Pujal Josep-Maria, Grinyó Josep M, Gil-Vernet Salvador, Caldes Anna, Hernández Pilar, Mestre Mariona, Encuentra Maite, Perez-Garcia Arianne, Gallardo David
Alloreactivity Unit, Translational Research Laboratory, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
Transplantation. 2007 Nov 15;84(9):1103-11. doi: 10.1097/01.tp.0000286172.57076.df.
The presence of a few circulating donor cells in recipient's blood was first thought to be only an epiphenomenon of solid organ transplantation, also called microchimerism, but several authors have suggested that these circulating cells may contribute to tolerance induction. This study aims to assess the rate of microchimerism after kidney transplantation and determine its influence on acute rejection in a 4-year follow-up.
A total of 84 single-kidney recipients were included for microchimerism detection and quantification 2, 6, 12, and 18 months after transplantation by specific detection of non-shared STR, VNTR, human leukocyte antigen-A, -B, -DRB1, and SRY alleles. Kinetic establishment of microchimerism was monitored in a double kidney transplanted recipient for 150 min after declamping and after 7 days.
Microchimerism was detected in 56.2% of kidney recipients 2 months after transplantation (M2): this fell to 30.1% at 12 months. In renal calcineurin inhibitor-based immunosuppression cohort (n=73), the microchimerism-negative group (n=32) showed 37.9% biopsy-proven acute rejection (BPAR), whereas in the microchimerism-positive group (n=41), no recipient did (P<0.001). Regardless of immunosuppression, BPAR incidence was 35.6% and 4.9%, respectively (P<0.001). Multivariate study showed microchimerism as a protective factor against BPAR (odds ratio: 8.3; 95% confidence interval: 1.8 to 37.9; P = 0.006), blinding other well-known rejection-risk variables. Microchimerism M2 presence did not correlate with a multifactorial critical outcome such as late graft loss.
Microchimerism was frequent after kidney transplantation and correlated with a significantly lower incidence of rejection. We propose that early microchimerism monitoring could help early detection of low rejection-risk recipients.